UltraSight

Cardiac Ultrasound with Real-time AI Guidance

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in March 2019 by Achi Ludomirsky, Yaron Lipman, and Itay Kezurer, UltraSight operates with 11–50 employees. The company has raised a total of $15.2M across 4 funding rounds from 4 investors. In June 2024, UltraSight collaborated with Mayo Clinic to advance next-generation cardiac care with AI.

Business overview

UltraSight develops AI-driven software to enhance the accessibility and efficiency of diagnostic imaging, specifically for cardiac ultrasound. Its core technology provides real-time guidance, enabling medical professionals to acquire timely and accurate cardiac ultrasound images. The company serves the healthcare industry, focusing on healthcare providers and operates within the digital healthcare, digital medical diagnostics, and medical devices sectors.

Strategic signal

In June 2024, UltraSight announced a collaboration with Mayo Clinic to advance next-generation cardiac care using AI. This partnership is a significant validation of UltraSight's technology and its potential to integrate into leading healthcare systems, signaling strong market adoption and strategic growth in the AI-powered medical diagnostics space.

Company Intelligence Q&A

What is UltraSight's primary mission?
UltraSight's mission is to make diagnostic imaging more accessible by empowering medical professionals to successfully acquire timely and accurate cardiac ultrasound images anywhere using its AI-driven software.
When did UltraSight receive FDA clearance for its AI-powered cardiac ultrasound technology?
The FDA granted clearance for UltraSight's AI-powered cardiac ultrasound technology in July 2023.
Which organization did UltraSight partner with to enable more accessible cardiac ultrasound for patients?
In June 2023, UltraSight partnered with EchoNous to enable more accessible cardiac ultrasound for patients.
When was UltraSight granted a patent for its real-time guidance ultrasound technology?
UltraSight was granted a patent for its real-time guidance ultrasound technology in February 2023.
What significant regulatory milestone did UltraSight achieve in August 2022?
In August 2022, UltraSight received CE Mark for its novel cardiac AI technology, allowing its use in Europe.

External links